Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance.

Cell death & disease

Mehlich D, Łomiak M, Sobiborowicz A, Mazan A, Dymerska D, Szewczyk ŁM, Mehlich A, Borowiec A, Prełowska MK, Gorczyński A, Jabłoński P, Iżycka-Świeszewska E, Nowis D, Marusiak AA.
PMID: 34839359
Cell Death Dis. 2021 Nov 27;12(12):1111. doi: 10.1038/s41419-021-04405-0.

Chemoresistance constitutes a major challenge in the treatment of triple-negative breast cancer (TNBC). Mixed-Lineage Kinase 4 (MLK4) is frequently amplified or overexpressed in TNBC where it facilitates the aggressive growth and migratory potential of breast cancer cells. However, the...

Cite
Mehlich D, Łomiak M, Sobiborowicz A, et al. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death Dis. 2021;12(12):1111doi: 10.1038/s41419-021-04405-0.
Mehlich, D., Łomiak, M., Sobiborowicz, A., Mazan, A., Dymerska, D., Szewczyk, �. �. M., Mehlich, A., Borowiec, A., Prełowska, M. K., Gorczyński, A., Jabłoński, P., Iżycka-Świeszewska, E., Nowis, D., & Marusiak, A. A. (2021). MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell death & disease, 12(12), 1111. https://doi.org/10.1038/s41419-021-04405-0
Mehlich, Dawid, et al. "MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance." Cell death & disease vol. 12,12 (2021): 1111. doi: https://doi.org/10.1038/s41419-021-04405-0
Mehlich D, Łomiak M, Sobiborowicz A, Mazan A, Dymerska D, Szewczyk ŁM, Mehlich A, Borowiec A, Prełowska MK, Gorczyński A, Jabłoński P, Iżycka-Świeszewska E, Nowis D, Marusiak AA. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death Dis. 2021 Nov 27;12(12):1111. doi: 10.1038/s41419-021-04405-0. PMID: 34839359; PMCID: PMC8627512.
Copy Download .nbib Format: NLM
MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance.

Cell death & disease

Mehlich D, Łomiak M, Sobiborowicz A, Mazan A, Dymerska D, Szewczyk ŁM, Mehlich A, Borowiec A, Prełowska MK, Gorczyński A, Jabłoński P, Iżycka-Świeszewska E, Nowis D, Marusiak AA.
PMID: 34839359
Cell Death Dis. 2021 Nov 27;12(12):1111. doi: 10.1038/s41419-021-04405-0.

Chemoresistance constitutes a major challenge in the treatment of triple-negative breast cancer (TNBC). Mixed-Lineage Kinase 4 (MLK4) is frequently amplified or overexpressed in TNBC where it facilitates the aggressive growth and migratory potential of breast cancer cells. However, the...

Cite
Mehlich D, Łomiak M, Sobiborowicz A, et al. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death Dis. 2021;12(12):1111doi: 10.1038/s41419-021-04405-0.
Mehlich, D., Łomiak, M., Sobiborowicz, A., Mazan, A., Dymerska, D., Szewczyk, �. �. M., Mehlich, A., Borowiec, A., Prełowska, M. K., Gorczyński, A., Jabłoński, P., Iżycka-Świeszewska, E., Nowis, D., & Marusiak, A. A. (2021). MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell death & disease, 12(12), 1111. https://doi.org/10.1038/s41419-021-04405-0
Mehlich, Dawid, et al. "MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance." Cell death & disease vol. 12,12 (2021): 1111. doi: https://doi.org/10.1038/s41419-021-04405-0
Mehlich D, Łomiak M, Sobiborowicz A, Mazan A, Dymerska D, Szewczyk ŁM, Mehlich A, Borowiec A, Prełowska MK, Gorczyński A, Jabłoński P, Iżycka-Świeszewska E, Nowis D, Marusiak AA. MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death Dis. 2021 Nov 27;12(12):1111. doi: 10.1038/s41419-021-04405-0. PMID: 34839359; PMCID: PMC8627512.
Copy Download .nbib Format: NLM
Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25].

Cancer letters

Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, Kaminska K, Marusiak AA, Nowis D.
PMID: 34872789
Cancer Lett. 2022 Feb 01;526:363. doi: 10.1016/j.canlet.2021.11.029. Epub 2021 Dec 04.

No abstract available.

Cite
Prelowska MK, Mehlich D, Ugurlu MT, et al. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer Lett. 2021;526:363doi: 10.1016/j.canlet.2021.11.029.
Prelowska, M. K., Mehlich, D., Ugurlu, M. T., Kedzierska, H., Cwiek, A., Kosnik, A., Kaminska, K., Marusiak, A. A., & Nowis, D. (2022). Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer letters, 526363. https://doi.org/10.1016/j.canlet.2021.11.029
Prelowska, Monika K, et al. "Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]." Cancer letters vol. 526 (2022): 363. doi: https://doi.org/10.1016/j.canlet.2021.11.029
Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, Kaminska K, Marusiak AA, Nowis D. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer Lett. 2022 Feb 01;526:363. doi: 10.1016/j.canlet.2021.11.029. Epub 2021 Dec 04. PMID: 34872789.
Copy Download .nbib Format: NLM
Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25].

Cancer letters

Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, Kaminska K, Marusiak AA, Nowis D.
PMID: 34872789
Cancer Lett. 2021 Dec 04; doi: 10.1016/j.canlet.2021.11.029. Epub 2021 Dec 04.

No abstract available.

Cite
Prelowska MK, Mehlich D, Ugurlu MT, et al. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer Lett. 2021;doi: 10.1016/j.canlet.2021.11.029.
Prelowska, M. K., Mehlich, D., Ugurlu, M. T., Kedzierska, H., Cwiek, A., Kosnik, A., Kaminska, K., Marusiak, A. A., & Nowis, D. (2021). Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer letters, . https://doi.org/10.1016/j.canlet.2021.11.029
Prelowska, Monika K, et al. "Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]." Cancer letters vol. (2021). doi: https://doi.org/10.1016/j.canlet.2021.11.029
Prelowska MK, Mehlich D, Ugurlu MT, Kedzierska H, Cwiek A, Kosnik A, Kaminska K, Marusiak AA, Nowis D. Corrigendum to "Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors" [Canc. Lett. 507 (2021) 13-25]. Cancer Lett. 2021 Dec 04; doi: 10.1016/j.canlet.2021.11.029. Epub 2021 Dec 04. PMID: 34872789.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries